Increased Circulating CXCL10 in Non-Segmental Vitiligo Concomitant with Autoimmune Thyroid Disease and Alopecia Areata = Increased Circulating CXCL10 in Non-Segmental Vitiligo Concomitant with Autoimmune Thyroid Disease and Alopecia Areata

다국어 초록 (Multilingual Abstract)

Background: Vitiligo is a common acquired pigmentary disease caused by destruction of epidermal melanocytes in underlying autoimmune response. Few studies have been focused on the role of chemokines in non-segmental vitiligo (NSV) concomitant with autoimmune thyroid disease (AITD) and alopecia areata (AA). Objective: The aim of this study was to determine the best serum biomarker for predictive role in the progression of vitiligo and to evaluate the influence of AA and/or AITD on vitiligo by using the biomarker. Methods: This prospective cohort study recruited 45 NSV patients: 14 without either AITD or AA, 12 with AITD, 11 with AA, and 8 with both AITD and AA. Serum levels of CXCL1, CXCL8, CXCL9, CXCL10, CXCL12, CXCL13, and CXCL16 were analyzed by ELISA. CXCR3 mRNA expression was detected on PBMCs by RT-PCR. Improvement was evaluated using repigmentation scales. Results: Serum CXCL10 levels, along with the expression of CXCR3 mRNA were higher in NSV patients with AITD or AA alone than in those without AITD or AA. Moreover, serum CXCL10 levels, along with the expression of CXCR3 mRNA were higher in NSV patients with both AITD and AA than in those with AITD or AA alone. Poorer repigmentation was observed in NSV patients with both AA and AITD than in those with AA or AITD alone. Conclusion: CXCL10 could be a biomarker to predict the progression of NSV. Dermatologists should pay much attention to those NSV patients concomitant with AITD and/or AA, for comorbidity might lead to more active autoimmune reaction. (Ann Dermatol 31(4) 393∼402, 2019)

참고문헌 (Reference)

1 McElwee KJ, "What causes alopecia areata" 22 : 609-626, 2013

2 Picardo M, "Vitiligo" 1 : 15011-, 2015

3 Rork JF, "Understanding autoimmunity of vitiligo and alopecia areata" 28 : 463-469, 2016

4 Fröhlich E, "Thyroid autoimmunity : role of antithyroid antibodies in thyroid and extra-thyroidal diseases" 8 : 521-, 2017

5 Vrijman C, "The prevalence of thyroid disease in patients with vitiligo : a systematic review" 167 : 1224-1235, 2012

6 Taïeb A, "The definition and assessment of vitiligo : a consensus report of the Vitiligo European Task Force" 20 : 27-35, 2007

7 Miniati A, "Stimulated human melanocytes express and release interleukin-8, which is inhibited by luteolin : relevance to early vitiligo" 39 : 54-57, 2014

8 Lee HT, "Serum BLC/CXCL13 concentrations and renal expression of CXCL13/CXCR5 in patients with systemic lupus erythematosus and lupus nephritis" 37 : 45-52, 2010

9 Stinco G, "Serological screening for autoimmune polyendocrine syndromes in patients with vitiligo" 26 : 1041-1042, 2012

10 Speeckaert R, "S100B is a potential disease activity marker in nonsegmental vitiligo" 137 : 1445-1453, 2017

11 Rotondi M, "Role of chemokines in endocrine autoimmune diseases" 28 : 492-520, 2007

12 Liu M, "Rethinking screening for thyroid autoimmunity in vitiligo" 75 : 1278-1280, 2016

13 Li S, "Oxidative stress drives CD8+ T-cell skin trafficking in patients with vitiligo through CXCL16 upregulation by activating the unfolded protein response in keratinocytes" 140 : 177-189, 2017

14 Spritz RA, "Novel vitiligo susceptibility loci on chromosomes 7(AIS2)and 8(AIS3), confirmation of SLEV1 on chromosome 17, and their roles in an autoimmune diathesis" 74 : 188-191, 2004

15 Gilhar A, "Lymphocytes, neuropeptides, and genes involved in alopecia areata" 117 : 2019-2027, 2007

16 Richmond JM, "Keratinocyte-derived chemokines orchestrate T-cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease" 137 : 350-358, 2017

17 Nanba T, "Increases of the Th1/Th2 cell ratio in severe Hashimoto's disease and in the proportion of Th17 cells in intractable Graves' disease" 19 : 495-501, 2009

18 Wang XX, "Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo" 174 : 1318-1326, 2016

19 Kim JY, "Impact of high-mobility group box 1 on melanocytic survival and its involvement in the pathogenesis of vitiligo" 176 : 1558-1568, 2017

20 Medici M, "Identification of novel genetic Loci associated with thyroid peroxidase antibodies and clinical thyroid disease" 10 : e1004123-, 2014

21 Lang KS, "HLA-A2 restricted, melanocyte-specific CD8(+)T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1" 116 : 891-897, 2001

22 Mockenhaupt M, "Evidence of involvement of CXC-chemokines in proliferation of cultivated human melanocytes" 12 : 597-601, 2003

23 Laberge G, "Early disease onset and increased risk of other autoimmune diseases in familial generalized vitiligo" 18 : 300-305, 2005

24 Maouia A, "Differential expression of CXCL9, CXCL10, and IFN-γ in vitiligo and alopecia areata patients" 30 : 259-261, 2017

25 Gill L, "Comorbid autoimmune diseases in patients with vitiligo : a cross-sectional study" 74 : 295-302, 2016

26 Ferrari SM, "Circulating CXCL10 is increased in nonsegmental vitiligo, in presence or absence of autoimmune thyroiditis" 16 : 946-950, 2017

27 Harris JE, "Cellular stress and innate inflammation in organspecific autoimmunity : lessons learned from vitiligo" 269 : 11-25, 2016

28 Van Raemdonck K, "CXCR3 ligands in disease and therapy" 26 : 311-327, 2015

29 Wutte N, "CXCL13 and B-cell activating factor as putative biomarkers in systemic sclerosis" 169 : 723-725, 2013

30 Rashighi M, "CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo" 6 : 223-, 2014

31 Gey A, "Autoimmune thyroid disease in vitiligo : multivariate analysis indicates intricate pathomechanisms" 168 : 756-761, 2013

32 van den Boorn JG, "Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients" 129 : 2220-2232, 2009

33 Speeckaert R, "Alterations of CXCL12in serum of patients with vitiligo" 137 : 1586-1588, 2017

34 Xing L, "Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition" 20 : 1043-1049, 2014

35 Campbell JD, "Allergic humans are hyporesponsive to a CXCR3 ligand-mediated Th1 immunity-promoting loop" 18 : 329-331, 2004